- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03823079
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
A Randomized Phase II Study of Recombinant Human Thrombopoietin (Rh-TPO) and Recombinant Human Interleukin-11 (rhIL-11) for Recurrent Colorectal Cancer (CRC) Patients With Thrombocytopenia
연구 개요
상태
상세 설명
연구 유형
등록 (예상)
단계
- 2 단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- The primary tumor is colorectal cancer, histologically proved recurrence or metastasis disease, or pelvic relapse within 6 months after oxaliplatin-based adjuvant chemotherapy.
- Not suitable for re-use of oxaliplatin and fluorouracil.
- No medication history of irinotecan.
- Lesions evaluable, and has indications for radiotherapy.
- UGT1A1*28 gene phenotype is 6/6 or 6/7
- Karnofsky physical condition score ≥ 70
- Baseline platelet counts are 25-75×10^9/L, other bone marrow reserve and liver and kidney function meet the requirements of radiotherapy
- Able to follow the program during the study period
- Sign the informed consent
Exclusion Criteria:
- Pregnant or breastfeeding women
- Those with other history of malignant disease in the past 5 years, except for cured skin cancer and cervical carcinoma in situ
- If there is an uncontrolled history of epilepsy, central nervous system disease or mental disorder, the investigator may determine that the clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance.
- Clinically severe (ie, active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring medication intervention (see appendix 12), or a history of myocardial infarction in the last 12 months
- Organ transplantation requires immunosuppressive therapy
- Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant diseases
- Subject blood routine and biochemical indicators do not meet the following criteria: hemoglobin ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; Alanine transaminase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal; alkaline phosphatase (ALP) ≤2.5 times the normal upper limit; serum total bilirubin <1.5 times the normal upper limit; serum creatinine <1 times the normal upper limit; serum albumin ≥ 30g / L
- Anyone who is allergic to any research medication
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: rhTPO arm
rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal) Concurrent Chemoradiotherapy: Radiation: judged according to the tumor site and radiotherapy purpose. Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7) Raltitrexed: 3 mg/m2 q3w |
rhTPO 300u/kg, subcutaneous injection, qd
80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
3mg/m2 q3w
in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
|
활성 비교기: rhIL-11 arm
rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal) Concurrent Chemoradiotherapy: Radiation: judged according to the tumor site and radiotherapy purpose. Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7) Raltitrexed: 3 mg/m2 q3w |
80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
3mg/m2 q3w
in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
rhIL-11 50ug/kg, subcutaneous injection, qd
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
the rate of recovery of platelet accounts
기간: From date of chemoradiation until the date of first documented recovery, assessed up to 6 months
|
From date of chemoradiation until the date of first documented recovery, assessed up to 6 months
|
the duration after returning to normal
기간: From date of first documented recovery until the date of first documented decrease of platelet accounts, assessed up to 6 months
|
From date of first documented recovery until the date of first documented decrease of platelet accounts, assessed up to 6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
cycles of concurrent chemotherapy patients received during radiotherapy
기간: through chemoradiation, an average of 5 weeks
|
through chemoradiation, an average of 5 weeks
|
|
change of participant quality of life during treatment as assessed by EORTC-quality of life questionnaire-C30
기간: at the beginning and the end of chemoradiation.
|
at the beginning and the end of chemoradiation.
|
|
change of participant quality of life during treatment as assessed by EuroQol-5 dimensional (EQ-5D) questionnaire
기간: at the beginning and the end of chemoradiation.
|
at the beginning and the end of chemoradiation.
|
|
the rate of pathological complete response.
기간: Surgery scheduled 6-8 weeks after the end of chemoradiation
|
pathological complete response (pCR) was defined no viable cancer cell under the examination of surgical resection specimen.
|
Surgery scheduled 6-8 weeks after the end of chemoradiation
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 의자: Zhen Zhang, MD, Fudan University
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- FDRT-009
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
rhTPO에 대한 임상 시험
-
Shandong UniversityThe Second Hospital of Hebei Medical University; The Affiliated Hospital of Qingdao University 그리고 다른 협력자들완전한
-
Wuhan Union Hospital, ChinaThe First Affiliated Hospital of Nanchang University; The Third Xiangya Hospital of Central... 그리고 다른 협력자들알려지지 않은
-
Institute of Hematology & Blood Diseases Hospital...Fosun Pharmaceutical Distribution Jiangsu co., Limited아직 모집하지 않음
-
Nanfang Hospital of Southern Medical UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen University 그리고 다른 협력자들알려지지 않은
-
Institute of Hematology & Blood Diseases Hospital완전한
-
Peking University People's Hospital알려지지 않은
-
Peking University People's Hospital알려지지 않은